Professional Education


  • Post Doctoral Fellowship, Stanford University, Clinical Fellowship in Pediatric Psychology (2012)
  • Doctor of Philosophy, Alliant International Universi (2011)
  • APA Internship, Children's Hospital Colorado, Child and Adolescent Psychology (2011)

Stanford Advisors


Current Research and Scholarly Interests


Research interests include examining neurophysiological development of interoceptive and emotional processing in children with psychiatric and genetic disorders, particularly PTSD, Fragile X Disorder and Eating Disorders.

Clinical interests focus on treating children, adolescents and young adults with PTSD, eating disorders, psychosomatic disorders, chronic pain and severe emotional disregulation. Common treatment approaches utilized include family based behavioral therapy, mentalization based psychotherapy, DBT, ACT, MBSR, CBT, biofeedback and psychodynamic psychotherapy.

Journal Articles


  • Interoceptive sensitivity deficits in women recovered from bulimia nervosa. Eating behaviors Klabunde, M., Acheson, D. T., Boutelle, K. N., Matthews, S. C., Kaye, W. H. 2013; 14 (4): 488-492

    Abstract

    Self-report studies suggest that patients with bulimia nervosa (BN) evidence difficulties with interoceptive awareness. Indeed, interoceptive deficits may persist after recovery of BN and may be a biological trait that predisposes symptom development in BN. However, no studies to date have directly assessed interoceptive sensitivity, or accuracy in detecting and perceiving internal body cues, in patients with or recovered from BN. Nine women who had recovered from BN and 10 healthy control women completed the Heart Beat Perception Task (HBPT) in which individuals were required to estimate the number of heartbeats between intervals of time. Accuracy scores were compared between groups. Significant differences were found between the groups on the HBPT ((F1,19) = 7.78, p = .013, Cohen's d = 1.16) when controlling for age. These results suggest that deficits in interoceptive sensitivity are present in individuals recovered from BN. Thus interoceptive deficits may be one factor that bridges the gap between brain dysfunction and symptom presentation in BN.

    View details for DOI 10.1016/j.eatbeh.2013.08.002

    View details for PubMedID 24183142

  • Altered insula activation during pain anticipation in individuals recovered from anorexia nervosa: Evidence of interoceptive dysregulation INTERNATIONAL JOURNAL OF EATING DISORDERS Strigo, I. A., Matthews, S. C., Simmons, A. N., Oberndorfer, T., Klabunde, M., Reinhardt, L. E., Kaye, W. H. 2013; 46 (1): 23-33

    Abstract

    Recent evidence raises the possibility that symptoms of anorexia nervosa (AN) could be related to impaired interoception. Pain is an interoceptive process with well-characterized neuroanatomical pathways that may overlap to a large degree with neural systems that may be dysregulated in individuals with AN, such as the insula.Functional magnetic resonance imaging (fMRI) was used to assess neural substrates of pain anticipation and processing in 10 healthy control women (CW) and 12 individuals recovered from AN (REC AN) in order to avoid the confounding effects of malnutrition. Painful heat stimuli were applied while different colors signaled the intensity of the upcoming stimuli.REC AN compared with CW showed greater activation within right anterior insula (rAI), dorsolateral prefrontal cortex (dlPFC) and cingulate during pain anticipation, and greater activation within dlPFC and decreased activation within posterior insula during painful stimulation. Greater anticipatory rAI activation correlated positively with alexithymic feelings in REC AN participants.REC AN showed a mismatch between anticipation and objective responses, suggesting altered integration and, possibly, disconnection between reported and actual interoceptive state. Alexithymia assessment provided additional evidence of an altered ability to accurately perceive bodily signals in women recovered from AN.

    View details for DOI 10.1002/eat.22045

    View details for Web of Science ID 000312300000004

    View details for PubMedID 22836447

  • Double-Blind Placebo-Controlled Trial of Quetiapine in Anorexia Nervosa EUROPEAN EATING DISORDERS REVIEW Powers, P. S., Klabunde, M., Kaye, W. 2012; 20 (4): 331-334

    Abstract

    Our objective is to determine whether quetiapine was superior to placebo in increasing weight or reducing core symptoms of anorexia nervosa as assessed by the Yale-Brown-Cornell Eating Disorder Scale and the Eating Disorder Inventory-2.Participants were randomised to 8 weeks of quetiapine or placebo.There are 21 participants who signed informed consent, 15 were randomised, 14 returned for at least one visit after receiving drug and 10 completed the study. There were no differences between drug and placebo in questionnaire scores, weight or measures of anxiety or depression.There was no difference between quetiapine and placebo on weight gain or core symptoms. Small effect sizes suggest that a higher number of participants would not increase significant differences between groups.

    View details for DOI 10.1002/erv.2169

    View details for Web of Science ID 000305507100012

    View details for PubMedID 22535517

  • Differential Weight Restoration on Olanzapine versus Fluoxetine in Identical Twins with Anorexia Nervosa INTERNATIONAL JOURNAL OF EATING DISORDERS Duvvuri, V., Cromley, T., Klabunde, M., Boutelle, K., Kaye, W. H. 2012; 45 (2): 294-297

    Abstract

    No studies have compared the response to selective serotonin reuptake inhibitors and atypical antipsychotics in anorexia nervosa. This case study examines such a comparison.This report describes a case of 12-year-old identical twins with anorexia nervosa, one of whom was treated with olanzapine and the other with fluoxetine, while undergoing family therapy.Twin A treated with fluoxetine went from 75 to 84.4% ideal body weight, while Twin B treated with olanzapine went from 72 to 99.9% ideal body weight over the course of 9 months.This case supports the need for adequately powered, controlled clinical trials to test the efficacy of olanzapine in adolescents presenting with anorexia nervosa.

    View details for DOI 10.1002/eat.20917

    View details for Web of Science ID 000301228500018

    View details for PubMedID 21344468

  • Is Anorexia Nervosa an Eating Disorder? How Neurobiology Can Help Understand Puzzling Behaviors A Collaborative Approach to Eating Disorders: Routledge Kaye, W., Bailer.U., & Klabunde, M. 2011